STOCK TITAN

Conduit Pharmaceuticals Inc. - $CDT STOCK NEWS

Welcome to our dedicated page for Conduit Pharmaceuticals news (Ticker: $CDT), a resource for investors and traders seeking the latest updates and insights on Conduit Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Conduit Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Conduit Pharmaceuticals's position in the market.

Rhea-AI Summary
Conduit Pharmaceuticals Inc. appoints Dr. Joanne Holland as Chief Scientific Officer and Dr. Jeff Lindeman as a consultant to strengthen its intellectual property portfolio. Dr. Holland brings over 20 years of experience in solid-form technology and holds numerous patents. Dr. Lindeman, an IP attorney, has over 30 years of experience in patent law. The company aims to maximize future value through strategic leadership additions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
management
-
Rhea-AI Summary
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) announced the opening of a state-of-the-art laboratory in Cambridge, UK, enhancing its development capabilities and intellectual property portfolio. The new facility will focus on solid form technology to maximize out-licensing value and streamline clinical trial operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.37%
Tags
none
-
Rhea-AI Summary
Conduit Pharmaceuticals Inc. CEO Dr. David Tapolczay is set to participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14, 2024. The event will include a presentation and one-on-one investor meetings. A live webcast and replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.42%
Tags
conferences
Rhea-AI Summary
Conduit Pharmaceuticals Inc. will be attending the 14th Annual Jefferies London Healthcare Conference. The conference will take place from November 14 to November 16.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
-
Rhea-AI Summary
Conduit Pharmaceuticals partners with ClinConnect for cocrystal development program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12%
Tags
partnership
-
Rhea-AI Summary
Conduit Pharmaceuticals completes business combination with Murphy Canyon Acquisition Corp, expects to commence trading on September 25, 2023. Pro forma enterprise value of approximately $720 million. Conduit shareholders will own approximately 90% of the combined company's common stock. Conduit receives approximately $20 million from the Offering. Conduit Pharmaceuticals led by experienced pharmaceutical industry veterans. Advisors include A.G.P./Alliance Global Partners and Sichenzia Ross Ference LLP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
Conduit Pharmaceuticals Inc.

Nasdaq:CDT

CDT Rankings

CDT Stock Data

224.44M
18.45M
86%
1.89%
0.07%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
SAN DIEGO